Celldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Position Lifted by Novo Holdings A S

by · The Markets Daily

Novo Holdings A S lifted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 13.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 963,663 shares of the biopharmaceutical company’s stock after purchasing an additional 113,663 shares during the quarter. Celldex Therapeutics comprises about 1.6% of Novo Holdings A S’s investment portfolio, making the stock its 18th largest holding. Novo Holdings A S owned 1.45% of Celldex Therapeutics worth $32,755,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Celldex Therapeutics by 16.3% during the 4th quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock worth $120,817,000 after buying an additional 427,827 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Celldex Therapeutics by 631.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after purchasing an additional 2,664,915 shares in the last quarter. Swiss National Bank lifted its position in Celldex Therapeutics by 17.8% in the first quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock worth $4,797,000 after purchasing an additional 17,300 shares during the period. Jennison Associates LLC boosted its stake in Celldex Therapeutics by 3,327.0% during the 1st quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock valued at $28,879,000 after purchasing an additional 668,002 shares in the last quarter. Finally, Bellevue Group AG increased its position in shares of Celldex Therapeutics by 15.7% during the 1st quarter. Bellevue Group AG now owns 2,796,615 shares of the biopharmaceutical company’s stock valued at $117,374,000 after purchasing an additional 380,319 shares during the period.

Celldex Therapeutics Stock Performance

Shares of NASDAQ:CLDX opened at $26.95 on Friday. The company has a market cap of $1.78 billion, a PE ratio of -9.46 and a beta of 1.55. The firm has a 50 day simple moving average of $35.82 and a 200 day simple moving average of $36.71. Celldex Therapeutics, Inc. has a 52 week low of $22.11 and a 52 week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. The firm had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. On average, equities analysts predict that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, September 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Monday, September 16th. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Friday, September 27th. Citigroup started coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 target price for the company. Finally, The Goldman Sachs Group began coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $62.25.

View Our Latest Stock Analysis on CLDX

Celldex Therapeutics Profile

(Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Featured Stories